Moderna (MRNA)
(Delayed Data from NSDQ)
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $86.91 +0.07 (0.08%) 7:04 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $86.91 +0.07 (0.08%) 7:04 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Zacks News
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
by Zacks Equity Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
Moderna (MRNA) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $175.26, moving -0.55% from the previous trading session.
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
Stock Market News for Jul 11, 2022
by Zacks Equity Research
Wall Street had a mixed day on Friday in a choppy session of trading.
Company News for Jul 8, 2022
by Zacks Equity Research
Companies In The News Are: GME, MRNA, LCID, SLP.
Novavax (NVAX) Stock Rallies 26.8% in a Month: Here's Why
by Zacks Equity Research
FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.
Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents
by Zacks Equity Research
Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.
Can Moderna (MRNA) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Pfizer, BioNTec and Moderna
by Zacks Equity Research
Pfizer, BioNTec and Moderna are part of Zacks Analyst top Blog.
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
by Sundeep Ganoria
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.
The Chef's Warehouse and AZEK have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
The Chef's Warehouse and AZEK are part of as Zacks Bull and Bear of the Day article.
FDA Panel Recommends Modifying COVID Jabs to Target Omicron
by Kinjel Shah
The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.
Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents
by Zacks Equity Research
EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
by Kinjel Shah
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
Moderna (MRNA) Reveals New Data on Bivalent COVID Booster
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.
Company News for Jun 23, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, KFY, XOM, WGO
Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More
by Zacks Equity Research
Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $129.99, marking a +1.53% move from the previous day.
FDA Authorizes PFE & MRNA's COVID Jabs for 6 Months & Older Kids
by Zacks Equity Research
FDA authorizes Pfizer (PFE) and BioNTech's Comirnaty for use in children aged six months through four years. Moderna's (MRNA) Spikevax gains EUA for use in individuals aged 6 months through 17 years.
The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna
by Zacks Equity Research
Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.
Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More
by Kinjel Shah
FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.